Compare $NGNE vs $RGNX | Chartloom

Compare

$NGNE vs $RGNX

Neurogene Inc · Regenxbio Inc

NGNE

Neurogene Inc

RGNX

Regenxbio Inc

Compare $NGNE vs $RGNX

Comparing Neurogene Inc and Regenxbio Inc

NGNENeurogene Inc

RGNXRegenxbio Inc

NGNENeurogene Inc

Market cap

$521M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

31.0%

52W performance

2.2%

FCF yield

-16.8%

RGNXRegenxbio Inc

Market cap

$511M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.95x

Rev growth (TTM)

12.0%

YTD performance

-40.5%

52W performance

-34.0%

FCF yield

-48.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NGNE

RGNX

Detailed metrics comparison

NGNE

Neurogene Inc

RGNX

Regenxbio Inc

Market Cap

NGNE$521M

RGNX$511M

Enterprise Value

NGNE$409M

RGNX$656M

Price

NGNE$26.40

RGNX$8.07

P/E Ratio

NGNEN/A

RGNXN/A

P/S Ratio

NGNE0.00x

RGNX2.93x

EV/Sales

NGNE0.00x

RGNX3.76x

EV/EBITDA

NGNE0.00x

RGNX5.30x

P/B Ratio

NGNE2.36x

RGNX6.83x

P/FCF Ratio

NGNEN/A

RGNXN/A

EV/FCF

NGNE-4.66x

RGNX-2.63x

PEG Ratio

NGNEN/A

RGNXN/A

Forward P/E (NTM)

NGNEN/A

RGNXN/A

Forward P/S (NTM)

NGNEN/A

RGNX5.95x

Revenue (TTM)

NGNE$0

RGNX$174M

Revenue Growth (YoY)

NGNEN/A

RGNX12.0%

Forward Rev Growth

NGNE127.3%

RGNX25.9%

Gross Margin (TTM)

NGNE0.0%

RGNX86.4%

Operating Margin (TTM)

NGNE0.0%

RGNX0.0%

EBITDA Margin (TTM)

NGNE0.0%

RGNX-85.3%

Net Margin (TTM)

NGNE0.0%

RGNX-112.6%

FCF Margin (TTM)

NGNEN/A

RGNX-143.1%

Net Income (TTM)

NGNE$-46M

RGNX$-196M

FCF (TTM)

NGNE$-88M

RGNX$-250M

EPS (TTM)

NGNE$0.00

RGNX-$3.71

ROE (TTM)

NGNE-2527.0%

RGNX-22007.0%

ROA (TTM)

NGNE-2325.0%

RGNX-4604.0%

ROIC (TTM)

NGNE-2527.0%

RGNX-7179.0%

Cash

NGNE$112M

RGNX$36M

Debt

NGNE$8K

RGNX$182M

Net Cash/Debt

NGNE$112M

RGNX$-145M

Current Ratio (TTM)

NGNE10.64x

RGNX2.86x

Quick Ratio (TTM)

NGNE10.53x

RGNX2.71x

Debt/Equity (TTM)

NGNE0.00x

RGNX2.53x

Debt/Assets (TTM)

NGNE0.0%

RGNX0.0%

Interest Coverage (TTM)

NGNEN/A

RGNXN/A

Net Debt/EBITDA (TTM)

NGNE0.00x

RGNX0.00x

Beta

NGNE1.71

RGNX1.21

52W Performance

NGNE2.2%

RGNX-34.0%

YTD Performance

NGNE31.0%

RGNX-40.5%

% from 52W High

NGNE-39.5%

RGNX-50.2%

% from 52W Low

NGNE65.7%

RGNX47.9%

Asset Turnover (TTM)

NGNE0.00x

RGNX0.41x

FCF Yield (TTM)

NGNE-16.8%

RGNX-48.9%

Earnings Yield (TTM)

NGNE-8.8%

RGNX-38.5%

Dividend Yield (TTM)

NGNEN/A

RGNXN/A

Rule of 40

NGNE0.0

RGNX-131.1

EV/GP/RG

NGNEN/A

RGNX0.15

Ticker research

View NGNE research View RGNX research

Metric	NGNE Neurogene Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$521M	$511M
Enterprise Value	$409M	$656M
Price	$26.40	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.93x
EV/Sales	0.00x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	2.36x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.66x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.95x
Revenue & Growth
Revenue (TTM)	$0	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	127.3%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-85.3%
Net Margin (TTM)	0.0%	-112.6%
FCF Margin (TTM)	N/A	-143.1%
Net Income (TTM)	$-46M	$-196M
FCF (TTM)	$-88M	$-250M
EPS (TTM)	$0.00	-$3.71
ROE (TTM)	-2527.0%	-22007.0%
ROA (TTM)	-2325.0%	-4604.0%
ROIC (TTM)	-2527.0%	-7179.0%
Financial Health
Cash	$112M	$36M
Debt	$8K	$182M
Net Cash/Debt	$112M	$-145M
Current Ratio (TTM)	10.64x	2.86x
Quick Ratio (TTM)	10.53x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.21
52W Performance	2.2%	-34.0%
YTD Performance	31.0%	-40.5%
% from 52W High	-39.5%	-50.2%
% from 52W Low	65.7%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-16.8%	-48.9%
Earnings Yield (TTM)	-8.8%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View NGNE research	View RGNX research

Valuation

P/S Ratio

NGNE

0.00x

RGNX

2.93x

EV/FCF

NGNE

-4.66x

RGNX

-2.63x

Growth & revenue

Revenue Growth TTM

RGNX

12.0%

Forward Revenue Growth

NGNE

127.3%

RGNX

25.9%

Profitability & performance

Gross Margin

RGNX

86.4%

NGNE

0.0%

ROE

NGNE

-2527.0%

RGNX

-22007.0%

FCF Yield %

NGNE

-16.8%

RGNX

-48.9%

52-Week Performance

NGNE

2.2%

RGNX

-34.0%

Detailed metrics comparison

NGNE

Neurogene Inc

RGNX

Regenxbio Inc

Market Cap

NGNE$521M

RGNX$511M

Enterprise Value

NGNE$409M

RGNX$656M

Price

NGNE$26.40

RGNX$8.07

P/E Ratio

NGNEN/A

RGNXN/A

P/S Ratio

NGNE0.00x

RGNX2.93x

EV/Sales

NGNE0.00x

RGNX3.76x

EV/EBITDA

NGNE0.00x

RGNX5.30x

P/B Ratio

NGNE2.36x

RGNX6.83x

P/FCF Ratio

NGNEN/A

RGNXN/A

EV/FCF

NGNE-4.66x

RGNX-2.63x

PEG Ratio

NGNEN/A

RGNXN/A

Forward P/E (NTM)

NGNEN/A

RGNXN/A

Forward P/S (NTM)

NGNEN/A

RGNX5.95x

Revenue (TTM)

NGNE$0

RGNX$174M

Revenue Growth (YoY)

NGNEN/A

RGNX12.0%

Forward Rev Growth

NGNE127.3%

RGNX25.9%

Gross Margin (TTM)

NGNE0.0%

RGNX86.4%

Operating Margin (TTM)

NGNE0.0%

RGNX0.0%

EBITDA Margin (TTM)

NGNE0.0%

RGNX-85.3%

Net Margin (TTM)

NGNE0.0%

RGNX-112.6%

FCF Margin (TTM)

NGNEN/A

RGNX-143.1%

Net Income (TTM)

NGNE$-46M

RGNX$-196M

FCF (TTM)

NGNE$-88M

RGNX$-250M

EPS (TTM)

NGNE$0.00

RGNX-$3.71

ROE (TTM)

NGNE-2527.0%

RGNX-22007.0%

ROA (TTM)

NGNE-2325.0%

RGNX-4604.0%

ROIC (TTM)

NGNE-2527.0%

RGNX-7179.0%

Cash

NGNE$112M

RGNX$36M

Debt

NGNE$8K

RGNX$182M

Net Cash/Debt

NGNE$112M

RGNX$-145M

Current Ratio (TTM)

NGNE10.64x

RGNX2.86x

Quick Ratio (TTM)

NGNE10.53x

RGNX2.71x

Debt/Equity (TTM)

NGNE0.00x

RGNX2.53x

Debt/Assets (TTM)

NGNE0.0%

RGNX0.0%

Interest Coverage (TTM)

NGNEN/A

RGNXN/A

Net Debt/EBITDA (TTM)

NGNE0.00x

RGNX0.00x

Beta

NGNE1.71

RGNX1.21

52W Performance

NGNE2.2%

RGNX-34.0%

YTD Performance

NGNE31.0%

RGNX-40.5%

% from 52W High

NGNE-39.5%

RGNX-50.2%

% from 52W Low

NGNE65.7%

RGNX47.9%

Asset Turnover (TTM)

NGNE0.00x

RGNX0.41x

FCF Yield (TTM)

NGNE-16.8%

RGNX-48.9%

Earnings Yield (TTM)

NGNE-8.8%

RGNX-38.5%

Dividend Yield (TTM)

NGNEN/A

RGNXN/A

Rule of 40

NGNE0.0

RGNX-131.1

EV/GP/RG

NGNEN/A

RGNX0.15

Ticker research

View NGNE research View RGNX research

Metric	NGNE Neurogene Inc	RGNX Regenxbio Inc
Market & Valuation
Market Cap	$521M	$511M
Enterprise Value	$409M	$656M
Price	$26.40	$8.07
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.93x
EV/Sales	0.00x	3.76x
EV/EBITDA	0.00x	5.30x
P/B Ratio	2.36x	6.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.66x	-2.63x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.95x
Revenue & Growth
Revenue (TTM)	$0	$174M
Revenue Growth (YoY)	N/A	12.0%
Forward Rev Growth	127.3%	25.9%
Profitability
Gross Margin (TTM)	0.0%	86.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-85.3%
Net Margin (TTM)	0.0%	-112.6%
FCF Margin (TTM)	N/A	-143.1%
Net Income (TTM)	$-46M	$-196M
FCF (TTM)	$-88M	$-250M
EPS (TTM)	$0.00	-$3.71
ROE (TTM)	-2527.0%	-22007.0%
ROA (TTM)	-2325.0%	-4604.0%
ROIC (TTM)	-2527.0%	-7179.0%
Financial Health
Cash	$112M	$36M
Debt	$8K	$182M
Net Cash/Debt	$112M	$-145M
Current Ratio (TTM)	10.64x	2.86x
Quick Ratio (TTM)	10.53x	2.71x
Debt/Equity (TTM)	0.00x	2.53x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.71	1.21
52W Performance	2.2%	-34.0%
YTD Performance	31.0%	-40.5%
% from 52W High	-39.5%	-50.2%
% from 52W Low	65.7%	47.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.41x
FCF Yield (TTM)	-16.8%	-48.9%
Earnings Yield (TTM)	-8.8%	-38.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-131.1
EV/GP/RG	N/A	0.15
Ticker research	View NGNE research	View RGNX research